^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Lenvima (lenvatinib)

    i
    Other names: E7080, E-7080, E 7080, ER 20349200, ER-203492-00, MK-7902, ER20349200, ER-20349200, MK7902, MK 7902
    Company:
    Eisai, Knight Therap, Merck (MSD)
    Drug class:
    Multi-tyrosine kinase inhibitor
    Related drugs:
    1d
    Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant (clinicaltrials.gov)
    P2, N=3, Terminated, Emory University | N=19 --> 3 | Trial completion date: Nov 2026 --> May 2025 | Recruiting --> Terminated | Trial primary completion date: Nov 2025 --> May 2025; Slow Accrual
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Lenvima (lenvatinib)
    1d
    HCC-SIGHT: A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=350, Recruiting, Fudan University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    5-fluorouracil • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • Stivarga (regorafenib) • oxaliplatin • Qibeian (iparomlimab/tuvonralimab)
    1d
    Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    2d
    Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=18, Active, not recruiting, Emory University | Trial completion date: Jan 2026 --> Dec 2026
    Trial completion date
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    2d
    Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC (clinicaltrials.gov)
    P1/2, N=80, Not yet recruiting, Zhejiang Haichang Biotech Co., Ltd.
    New P1/2 trial
    |
    Lenvima (lenvatinib)
    3d
    Multi-Omics and Machine Learning-Uncovered FLT1-Mediated Epithelial-Endothelial Crosstalk in Cellular Senescence Driving Clear Cell Renal Cell Carcinoma Malignancy. (PubMed, FASEB J)
    For patients with high FLT1 expression, a combination therapy targeting this network-screened via molecular docking and dynamics simulations-may improve prognosis. This includes FLT1 inhibitors (Sorafenib, Regorafenib, Lenvatinib), supplemented by AKT1 inhibitors (Capivasertib) and VEGFA inhibitors (Bevacizumab) to suppress FLT1-associated malignant cell populations.
    Journal • IO biomarker
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1) • FLT1 (Fms-related tyrosine kinase 1)
    |
    Avastin (bevacizumab) • sorafenib • Lenvima (lenvatinib) • Stivarga (regorafenib) • Truqap (capivasertib)
    5d
    The KRT15 and KRT81 complex promotes lenvatinib resistance in thyroid cancer by upregulating DGKB mediated lipid metabolism. (PubMed, Sci Rep)
    This study illustrates a novel mechanism of cytoskeletal proteins involvement in metabolic adaptation of drug-resistant thyroid cancer cells. The KRT15-KRT81-DGKB pathway is a promising therapeutic target, particularly in combination with lenvatinib, for refractory thyroid cancer patients.
    Journal
    |
    ACOX1 (Acyl-CoA Oxidase 1) • CPT1A (Carnitine Palmitoyltransferase 1A)
    |
    Lenvima (lenvatinib)
    5d
    A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma (clinicaltrials.gov)
    P=N/A, N=25, Not yet recruiting, Tongji Hospital
    New trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • Jin Beixin (firsekibart)
    5d
    Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer (clinicaltrials.gov)
    P3, N=400, Not yet recruiting, Tongji Hospital
    New P3 trial
    |
    Tyvyt (sintilimab) • Lenvima (lenvatinib)
    5d
    CHANCE2202: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC (clinicaltrials.gov)
    P=N/A, N=941, Completed, Zhongda Hospital | Recruiting --> Completed | N=220 --> 941 | Trial completion date: Sep 2023 --> Sep 2025
    Trial completion • Enrollment change • Trial completion date
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • sorafenib • Tyvyt (sintilimab) • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • AiTan (rivoceranib) • Zepsun (donafenib)
    5d
    Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line Treatment (clinicaltrials.gov)
    P=N/A, N=200, Completed, Sun Yat-sen University
    New trial
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Tyvyt (sintilimab) • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • Stivarga (regorafenib)
    6d
    CHANCE2201: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC (clinicaltrials.gov)
    P=N/A, N=1244, Completed, Zhongda Hospital | Recruiting --> Completed | N=474 --> 1244
    Trial completion • Enrollment change
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • sorafenib • Tyvyt (sintilimab) • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • AiTan (rivoceranib) • Zepsun (donafenib)